VIEMED HEALTHCARE, INC. — Form 8-K
Filed August 20, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 22/100
What the filing says
VieMed (market cap ~$239M) reported FY2025 net revenue of $270.3M (+21% YoY), Adjusted EBITDA of $61.4M (+20% YoY), and free cash flow of $28.1M. 2Q2026 showed 24% YoY revenue growth to $78.1M with 44% YoY PAP therapy patient growth and 4% YoY vent patient growth. The company issued FY2026 guidance of $314-320M revenue and $64-68M Adjusted EBITDA, authorized a new 5% share repurchase program, and holds $0M net debt with $46M credit facility availability. No specific acquisition, financing event, or material contract is disclosed in this investor presentation—it is a routine growth-stage update.
Why this rating
Routine investor presentation disclosing historical results and guidance; no transaction, material contract change, or discontinuation announced. All figures are consistent with prior public disclosures.
See more from August 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.